A combination therapy of whole lung lavage and GM-CSF inhalation in pulmonary alveolar proteinosis.
Systemic and inhalation therapy of granulocyte-macrophage colony-stimulating factor (GM-CSF) is usually effective in controlling autoimmune pulmonary alveolar proteinosis (PAP), but some cases are refractory to GM-CSF therapy and subjected to whole lung lavage (WLL). A 9-year-old girl developed severe respiratory failure due to autoimmune PAP was treated with inhalational 250 microg of GM-CSF daily, however, it was ineffective. Unilateral WLL was performed three times and subsequent GM-CSF inhalation therapy yielded marked physiological and radiological improvement and was continued for 1 year.
Yamamoto
Hajime
H
Department of Pediatrics, Aichi Medical University School of Medicine, Aichi, Japan.
Yamaguchi
Etsuro
E
Agata
Hiroatsu
H
Kandatsu
Nobuhisa
N
Komatsu
Toru
T
Kawai
Seiko
S
Baba
Kenji
K
Awaya
Tomonari
T
Nishikomori
Ryuta
R
Tsurusawa
Masahito
M
Nakata
Koh
K
D000280:Administration, Inhalation; D018893:Bronchoalveolar Lavage; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D011649:Pulmonary Alveolar Proteinosis / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome
D016178:Granulocyte-Macrophage Colony-Stimulating Factor